Bare Iron Oxide Nanoparticles as Drug Delivery Carrier for the Short Cationic Peptide Lasioglossin
Bioseparation Engineering Group, Department of Mechanical Engineering, Technical University of Munich, 80333 München, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Serge Mordon
Pharmaceuticals 2021, 14(5), 405; https://doi.org/10.3390/ph14050405
Received: 23 March 2021
/
Revised: 20 April 2021
/
Accepted: 21 April 2021
/
Published: 24 April 2021
(This article belongs to the Special Issue Nanoparticle-Mediated Drug Delivery, Imaging, and Control of Cellular Functions)
New drug delivery systems are a potential solution for administering drugs to reduce common side effects of traditional methods, such as in cancer therapy. Iron oxide nanoparticles (IONs) can increase the drugs’ biological activity through high binding efficiency and magnetically targeted drug delivery. Understanding the adsorption and release process of a drug to the carrier material plays a significant role in research to generate an applicable and controlled drug delivery system. This contribution focuses on the binding patterns of the peptide lasioglossin III from bee venom on bare IONs. Lasioglossin has a high antimicrobial behavior and due to its cationic properties, it has high binding potential. Considering the influence of pH, the buffer type, the particle concentration, and time, the highest drug loading of 22.7% is achieved in phosphate-buffered saline. Analysis of the desorption conditions revealed temperature and salt concentration sensitivity. The nanoparticles and peptide-ION complexes are analyzed with dynamic light scattering, zeta potential, and infrared spectroscopy. Additionally, cytotoxicity experiments performed on Escherichia coli show higher antimicrobial activity of bound lasioglossin than of the free peptide. Therefore, bare IONs are an interesting platform material for the development of drug-delivery carriers for cationic peptides.
View Full-Text
Keywords:
iron oxide nanoparticles; magnetically controlled drug delivery; cationic peptide; lasioglossin; agglomeration behavior in human serum; antimicrobial behavior
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
- Supplementary File 1:
ZIP-Document (ZIP, 974 KiB)
MDPI and ACS Style
Turrina, C.; Berensmeier, S.; Schwaminger, S.P. Bare Iron Oxide Nanoparticles as Drug Delivery Carrier for the Short Cationic Peptide Lasioglossin. Pharmaceuticals 2021, 14, 405. https://doi.org/10.3390/ph14050405
AMA Style
Turrina C, Berensmeier S, Schwaminger SP. Bare Iron Oxide Nanoparticles as Drug Delivery Carrier for the Short Cationic Peptide Lasioglossin. Pharmaceuticals. 2021; 14(5):405. https://doi.org/10.3390/ph14050405
Chicago/Turabian StyleTurrina, Chiara, Sonja Berensmeier, and Sebastian P. Schwaminger. 2021. "Bare Iron Oxide Nanoparticles as Drug Delivery Carrier for the Short Cationic Peptide Lasioglossin" Pharmaceuticals 14, no. 5: 405. https://doi.org/10.3390/ph14050405
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
